| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 08/14/2001 | US6274148 Hepatitis C virus asialoglycoproteins |
| 08/14/2001 | US6274146 Biologically active phytogenous proteoglycan and a method of making thereof |
| 08/14/2001 | US6274144 Method for generating antibodies to saccharide fragments |
| 08/14/2001 | US6274139 For therapy of bacterial infections |
| 08/14/2001 | CA2243570C Mixture of recombinant vaccinia vectors as polyenv vaccines for hiv |
| 08/14/2001 | CA2226406C Novel pyridone carboxylic acid derivatives |
| 08/14/2001 | CA2185155C Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
| 08/14/2001 | CA2168560C Substituted oxazine and thiazine oxazolidinone antimicrobials |
| 08/14/2001 | CA2159640C Second messenger cell signaling inhibitors |
| 08/14/2001 | CA2037959C Cyclohexapeptides compound |
| 08/14/2001 | CA1341285C Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines |
| 08/10/2001 | WO2000047595A1 Ether type lipid a1-carboxylic acid analogues |
| 08/10/2001 | CA2362246A1 Ether type lipid a1-carboxylic acid analogues |
| 08/09/2001 | WO2001057267A1 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 08/09/2001 | WO2001057261A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides |
| 08/09/2001 | WO2001057226A1 Humanized anti-ccr2 antibodies and methods of use therefor |
| 08/09/2001 | WO2001057193A2 Protein c derivatives |
| 08/09/2001 | WO2001057175A2 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides |
| 08/09/2001 | WO2001057085A2 G-protein coupled receptors |
| 08/09/2001 | WO2001057079A2 C1 inhibitor produced in the milk of transgenic mammals |
| 08/09/2001 | WO2001057074A1 Ligands for fpr class receptors that induce a host immune response to a pathogen or inhibit hiv infection |
| 08/09/2001 | WO2001057072A2 Pharmacologically active antiviral peptides and methods of their use |
| 08/09/2001 | WO2001057071A2 Glycopeptide derivatives having antibiotic activity |
| 08/09/2001 | WO2001057060A1 Bcl-2-like polynucleotides, polypeptides, and antibodies |
| 08/09/2001 | WO2001057042A2 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy |
| 08/09/2001 | WO2001057041A1 1-methylcarbapenem compounds |
| 08/09/2001 | WO2001057036A1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes |
| 08/09/2001 | WO2001057026A1 Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| 08/09/2001 | WO2001057025A1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| 08/09/2001 | WO2001057023A1 Heterocyclic amide derivatives |
| 08/09/2001 | WO2001057022A2 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | WO2001057008A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| 08/09/2001 | WO2001056993A2 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | WO2001056987A1 Tosylproline analogs as thymidylate synthase inhibitors |
| 08/09/2001 | WO2001056610A1 Stabilised pharmaceutical compositions and process for their preparation comprising an antibiotic and an expectorant |
| 08/09/2001 | WO2001056602A2 Cd40 ligand adjuvant for respiratory syncytial virus |
| 08/09/2001 | WO2001056600A1 Method of controlling the qualities of attenuated pox vaccine |
| 08/09/2001 | WO2001056591A1 vMIP-II PEPTIDE ANTAGONISTS OF CXCR4 |
| 08/09/2001 | WO2001056562A1 Stable emulsion compositions |
| 08/09/2001 | WO2001056561A1 Preventives for viral infection |
| 08/09/2001 | WO2001056554A2 Use of retinoid-type compounds as antibacterial agents |
| 08/09/2001 | WO2001056553A2 Pharmaceutically active aromatic guanylhydrazones |
| 08/09/2001 | WO2001056383A1 Compositions and methods for treatment of toxoplasma gondii and other apicomplexans |
| 08/09/2001 | WO2001056358A2 Enhanced propertied pesticides |
| 08/09/2001 | WO2001056355A2 Human immunodeficiency virus vaccine |
| 08/09/2001 | WO2001032596A8 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 08/09/2001 | WO2001019814A3 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 08/09/2001 | WO2001010901A3 Antimicrobial histone h1 compositions, kits, and methods of use thereof |
| 08/09/2001 | WO2001010834A9 Antibacterial agents |
| 08/09/2001 | WO2001006988A3 Super-active porcine growth hormone releasing hormone analog |
| 08/09/2001 | WO2001004318A3 Myxoma virus genes for immune modulation |
| 08/09/2001 | WO2001004316A3 Antigenic meningococcal peptides |
| 08/09/2001 | WO2001002017A3 Erythropoietin conjugates with polyethylenglycol |
| 08/09/2001 | WO2000077216A3 Porcine circovirus vaccine in recombinant poxvirus |
| 08/09/2001 | WO2000073324A9 Modulation of gene expression in gastrointestinal inflammation |
| 08/09/2001 | WO2000070046A9 Secreted polypeptides and corresponding polynucleotides |
| 08/09/2001 | WO2000069895A3 Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins |
| 08/09/2001 | WO2000066173A3 Targeting of infectious agents bearing host cell proteins |
| 08/09/2001 | WO2000066100A3 2r,4s-hydroxyitraconazole isomers |
| 08/09/2001 | WO2000066094A3 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents |
| 08/09/2001 | WO2000055072A3 Aerosol metering valve |
| 08/09/2001 | WO2000047554A3 INHIBITORS OF FACTOR Xa |
| 08/09/2001 | WO2000015202A3 Topical application products |
| 08/09/2001 | US20010012895 Therapy for hair loss in mammals; drug resistance; nervous system disorders |
| 08/09/2001 | US20010012889 36 human secreted proteins |
| 08/09/2001 | US20010012885 Conjugate consisting of an active substance and a non-exogeneous native protein |
| 08/09/2001 | US20010012845 Adminstering an E-type prostaglandin ligand and a cyclooxygenase-2 enzyme selective inhibitor compound in combination with a carrier to treat inflammation |
| 08/09/2001 | US20010012842 Lomefloxacin, or a pharmaceutically acceptable salt free of its (R)-stereoismomer is useful for treating infections, but insufficient to cause adverse effect associated with administration of racemic lomefloxacin |
| 08/09/2001 | US20010012840 Topical transdermal treatments |
| 08/09/2001 | US20010012837 Anti-ulcer composition |
| 08/09/2001 | US20010012518 Oral dosage |
| 08/09/2001 | US20010012512 Non-virulent porphyromonas gingivalis mutant |
| 08/09/2001 | EP1143950A3 Topical application products |
| 08/09/2001 | DE19953517C1 Verwendung von Treosulfan zur Konditionierung von Patienten vor Knochemarktransplantation oder Blutstammzelltransplantation Use of treosulphan for conditioning of patients before Knochemarktransplantation or blood stem cell transplantation |
| 08/09/2001 | CA2399982A1 G-protein coupled receptors |
| 08/09/2001 | CA2399686A1 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 08/09/2001 | CA2399649A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides |
| 08/09/2001 | CA2399644A1 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides |
| 08/09/2001 | CA2399267A1 Protein c derivatives |
| 08/09/2001 | CA2399214A1 Novel heterocyclic amide derivatives |
| 08/09/2001 | CA2399080A1 Humanized anti-ccr2 antibodies and methods of use therefor |
| 08/09/2001 | CA2399032A1 Ligands for fpr class receptors that induce a host immune response to a pathogen or inhibit hiv infection |
| 08/09/2001 | CA2398996A1 Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| 08/09/2001 | CA2398816A1 Human immunodeficiency virus vaccine |
| 08/09/2001 | CA2398754A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| 08/09/2001 | CA2398752A1 Tosylproline analogs as thymidylate synthase inhibitors |
| 08/09/2001 | CA2398255A1 Bcl-2-like polynucleotides, polypeptides, and antibodies |
| 08/09/2001 | CA2369076A1 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | CA2369056A1 Vmip-ii peptide antagonists of cxcr4 |
| 08/08/2001 | EP1122261A2 13 and 14-membered antibacterial macrolides |
| 08/08/2001 | EP1122245A2 2-Amino-benzoxazinones for the treatment of viral infections |
| 08/08/2001 | EP1121940A1 Pharmaceutical compositions comprising an antibiotic and bromhexine, and process for their preparation |
| 08/08/2001 | EP1121938A2 Prevention of sudden infant death |
| 08/08/2001 | EP1121444A2 Protein kinase homologs |
| 08/08/2001 | EP1121430A1 Human isre-binding protein |
| 08/08/2001 | EP1121425A1 Stabilized bioactive peptides and methods of identification, synthesis and use |
| 08/08/2001 | EP1121420A2 Hepatitis a vaccines |
| 08/08/2001 | EP1121419A1 Tnfr related gene 12 |
| 08/08/2001 | EP1121382A2 Interferon-beta fusion proteins and uses |
| 08/08/2001 | EP1121372A1 Adenine derivatives |